CO5261612A1 - Inhibidores de girasa y usos de esta - Google Patents

Inhibidores de girasa y usos de esta

Info

Publication number
CO5261612A1
CO5261612A1 CO01003497A CO01003497A CO5261612A1 CO 5261612 A1 CO5261612 A1 CO 5261612A1 CO 01003497 A CO01003497 A CO 01003497A CO 01003497 A CO01003497 A CO 01003497A CO 5261612 A1 CO5261612 A1 CO 5261612A1
Authority
CO
Colombia
Prior art keywords
aliphatic
ring
optionally substituted
hydrogen
heteroaryl
Prior art date
Application number
CO01003497A
Other languages
English (en)
Inventor
Paul S Charifson
Dean Stamos
Michael Badia
Anne-Laure Grillot
Steven Ronkin
Martin Trudeau
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of CO5261612A1 publication Critical patent/CO5261612A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un método para tratar una infección bacterial en un mamífero en necesidad de ello, comprende la etapa de administrar a dicho mamífero una cantidad terapéuticamente efectiva de un compuesto que tiene la fórmula: <EMI FILE="01003497_1" ID="1" IMF=JPEG >O una sal farmacéuticamente aceptable de la misma, en donde R1 es un grupo opcionalmente sustituido seleccionado a partir de un grupo alifático con 1 a 6 átomos de carbono, -C(R4)2(CH2)Nnrcor, -C(R4)=N-OR, -C(R4)=N-OC(=O) (C1-6 alifático), C(R4)=NNRCRO, -C(R4)=NN( R )2, -(R4)2(CH2)nNRCO2 (C1-6 alifático), -CO2(C1-6 alifático), -CON(R)2, C(R4)2(CH2)nCON(R)2(CH2)nSO2N(R)2, -C(R4)2(CH2)nSO2N(R)2, -CONH-OR, SO2N(R)2 o -C(R4)2NRSO2(C1-6 alifático), n es cero o uno cada R es independientemente seleccionado de hidrógeno o un grupo alifático C1-6 opcionalmente sustituido; R2 se selecciona de hidrógeno o, cuando R1 es -CO2(C1-3 alifático), R2 se selecciona además de -halo -CN, - C1-4 alifático, un heterocíclico de 3 a 5 miembros, o un heteroarilo de 5 miembros; El anillo A es un anillo de heteroarilo seleccionado de tiazol, oxazol, imidazol o pirazol, en donde dicho imidazol esta opcionalmente unido a un puente C1-3 de un nitrógeno de anillo de imidazol a Ar para formar un anillo fusionado de 5 a 7 miembros; Z es C-R3 o N-R3; R3 es -(CH2)pN(R5)2 o un grupo opcionalmente sustituido seleccionado de C1-6 alifático, heterocíclico, heterocicloalquilo, arilo, aralquilo, heteroarilo o heteroaralquilo; Cada R4 es independientemente seleccionado de hidrógeno, Un grupo alifático C1-6 opcionalmente sustituido, o dos R4 tomados juntos con el carbono al cual ellos están unidos para formar un anillo alifático de 3 a 6 miembros; Cada R5 es independientemente seleccionado de hidrógeno, un grupo alifático C1-4, o dos R5 tomados junto con el nitrógeno al cual ellos están unidos para formar un anillo heterocíclico de 5 a 6 miembros; P es un entero de cero a 4 cuando z es C-R3 o un entero de 1 a 4 cuando z es N-R3; yAr es anillo de arilo heteroarilo, o heterocíclico opcionalmente sustituido.
CO01003497A 2000-01-18 2001-01-18 Inhibidores de girasa y usos de esta CO5261612A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17667100P 2000-01-18 2000-01-18
US25433100P 2000-12-08 2000-12-08

Publications (1)

Publication Number Publication Date
CO5261612A1 true CO5261612A1 (es) 2003-03-31

Family

ID=26872470

Family Applications (1)

Application Number Title Priority Date Filing Date
CO01003497A CO5261612A1 (es) 2000-01-18 2001-01-18 Inhibidores de girasa y usos de esta

Country Status (23)

Country Link
US (2) US6608087B1 (es)
EP (1) EP1251848B1 (es)
JP (1) JP2003520233A (es)
CN (1) CN1230166C (es)
AR (1) AR027518A1 (es)
AT (1) ATE269701T1 (es)
AU (1) AU782883B2 (es)
BR (1) BR0107713A (es)
CA (1) CA2397686A1 (es)
CO (1) CO5261612A1 (es)
DE (1) DE60103974T2 (es)
DK (1) DK1251848T3 (es)
EA (1) EA005680B1 (es)
ES (1) ES2222336T3 (es)
HK (1) HK1053984B (es)
MX (1) MXPA02007134A (es)
MY (1) MY133572A (es)
NZ (1) NZ520628A (es)
PT (1) PT1251848E (es)
SI (1) SI1251848T1 (es)
TR (1) TR200401735T4 (es)
TW (1) TWI287449B (es)
WO (1) WO2001052845A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002088101A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
CN100502863C (zh) * 2001-08-13 2009-06-24 詹森药业有限公司 2,4,5-三取代噻唑衍生物和它们的抗炎活性
US6984652B2 (en) * 2003-09-05 2006-01-10 Warner-Lambert Company Llc Gyrase inhibitors
TW200526626A (en) 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
FR2865733B1 (fr) * 2004-02-04 2007-10-12 Merck Sante Sas Derives de thiazolylimidazole, leurs procedes de preparation, les compositions pharmaceutiques qui les contiennent et leurs applications en medecine
US20080234132A1 (en) * 2004-11-19 2008-09-25 Laurence Coquin Microcin B17 Analogs And Methods For Their Preparation And Use
UA94901C2 (ru) 2005-02-18 2011-06-25 Астразенека Аб Антибактериальные производные пиперидина
WO2007095187A2 (en) * 2006-02-13 2007-08-23 Trustees Of Boston University Compositions and methods for antibiotic potentiation and drug discovery
EP3025653B1 (en) 2006-06-21 2021-06-16 Cook Biotech Incorporated Fistula grafts useful for treating gastrointestinal fistulae
US20100234348A1 (en) * 2006-08-04 2010-09-16 Trustees Of Boston University Compositions and methods for potentiating antibiotic activity
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
KR20100095430A (ko) * 2007-11-02 2010-08-30 메틸진 인크. 히스톤 탈아세틸화효소의 저해물질
JP5581219B2 (ja) 2008-01-25 2014-08-27 ミレニアム ファーマシューティカルズ， インコーポレイテッド チオフェンおよびホスファチジルイノシトール３−キナーゼ（ｐｉ３ｋ）阻害薬としてのその使用
US8865732B2 (en) * 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
WO2009115572A2 (en) * 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
JPWO2010007943A1 (ja) * 2008-07-17 2012-01-05 旭化成ファーマ株式会社 含窒素複素環化合物
PE20110843A1 (es) 2008-09-22 2011-12-08 Cayman Chem Co Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica
TW201026694A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9090601B2 (en) * 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
TW201102065A (en) 2009-05-29 2011-01-16 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
WO2011024004A1 (en) 2009-08-26 2011-03-03 Astrazeneca Ab Heterocyclic urea derivatives useful for treatment of bacterial infection
AU2010341229A1 (en) * 2009-12-17 2012-08-02 Merck Patent Gmbh Sphingosine kinase inhibitors
WO2012021615A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
TW201217365A (en) 2010-08-11 2012-05-01 Millennium Pharm Inc Heteroaryls and uses thereof
KR20140091462A (ko) 2010-10-13 2014-07-21 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 그의 용도
CN102911173A (zh) * 2012-11-08 2013-02-06 苏州施亚生物科技有限公司 5,6,7,8-四氢-2H-吡啶并[4,3-c]哒嗪-3-酮的合成方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
AU2015212495A1 (en) 2014-02-03 2016-08-18 Spero Gyrase, Inc. Antibacterial combinations comprising polymyxin
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR102341660B1 (ko) 2016-09-19 2021-12-23 노파르티스 아게 Raf 억제제 및 erk 억제제를 포함하는 치료적 조합
JPWO2018174288A1 (ja) 2017-03-24 2020-01-23 大正製薬株式会社 ２（１ｈ）−キノリノン誘導体
US11666555B2 (en) 2017-05-17 2023-06-06 Drexel University RelA inhibitors for biofilm disruption
US20210323957A1 (en) 2018-09-03 2021-10-21 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
WO2022129327A1 (en) 2020-12-17 2022-06-23 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity
WO2024112201A1 (en) * 2022-11-24 2024-05-30 Universiteit Leiden Dna gyrase inhibitors
WO2024145662A1 (en) * 2022-12-30 2024-07-04 Altay Therapeutics, Inc. 2-substituted thiazole and benzothiazole compositions and methods as dux4 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925659A (en) * 1996-05-07 1999-07-20 Merck & Co., Inc. Antibacterial agents
RU2173147C2 (ru) * 1996-05-09 2001-09-10 Санкио Компани Лимитед Применение производных 1-метилкарбопенема, антибактериальная в отношении helicobacter pylori композиция, содержащая в качестве активного ингредиента 1-метилкарбопенемовые производные и способ профилактики или лечения инфекционных заболеваний

Also Published As

Publication number Publication date
US6608087B1 (en) 2003-08-19
DE60103974T2 (de) 2005-06-30
DK1251848T3 (da) 2004-10-18
PT1251848E (pt) 2004-10-29
CN1400898A (zh) 2003-03-05
BR0107713A (pt) 2002-11-19
EP1251848B1 (en) 2004-06-23
JP2003520233A (ja) 2003-07-02
SI1251848T1 (en) 2004-12-31
EA200200769A1 (ru) 2002-12-26
NZ520628A (en) 2004-05-28
HK1053984B (zh) 2006-07-28
CA2397686A1 (en) 2001-07-26
TR200401735T4 (tr) 2004-08-23
WO2001052845A1 (en) 2001-07-26
DE60103974D1 (de) 2004-07-29
EA005680B1 (ru) 2005-04-28
AU782883B2 (en) 2005-09-08
MY133572A (en) 2007-11-30
EP1251848A1 (en) 2002-10-30
ATE269701T1 (de) 2004-07-15
US6930116B2 (en) 2005-08-16
HK1053984A1 (en) 2003-11-14
TWI287449B (en) 2007-10-01
AU3094001A (en) 2001-07-31
AR027518A1 (es) 2003-04-02
ES2222336T3 (es) 2005-02-01
CN1230166C (zh) 2005-12-07
US20040024030A1 (en) 2004-02-05
MXPA02007134A (es) 2003-03-27

Similar Documents

Publication Publication Date Title
CO5261612A1 (es) Inhibidores de girasa y usos de esta
CO5170501A1 (es) AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO
ATE250582T1 (de) Chinolinderivate als mek enzym-inhibitoren
CO5180629A1 (es) Pirimidina-2,4,6-ttrionas inhibidores de metaloproteinasas
CO5200785A1 (es) Uso terapeutico de quinazolina
EA200200078A1 (ru) Птеридиноны в качестве ингибиторов киназ
DE60140127D1 (en) Dihydroxypyrimidin-carbonsäuren als virale polymerase inhibitoren
CA2514220A1 (en) Ep4 receptor antagonists
ID29452A (id) 4-okso-1,4-dihidro-3-quinolinkarboksamida sebagai agen-agen antivirus
CO5251463A1 (es) Compuestos heterociclicos y composicion farmaceutica que coniene dichos compuestos
DE60006099D1 (de) Chinolinderivate als mek enzym-inhibitoren
CO5080804A1 (es) Derivados biciclicos del acido hidroxamico
ATE361916T1 (de) Pyrimidine verbindungen
NO982913L (no) Kinolin- og kinazolinforbindelser nyttige i terapi
CO5280070A1 (es) Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular
AR036042A1 (es) Derivados aralquilsufonil-3-(pirrol-2-ilmetiliden)-2-indolinona, sus composiciones farmaceuticas y metodo para la modulacion de la actividad catalitica de una proteina quinasa
EA200301094A1 (ru) Аминопроизводные как ингибиторы протеазы
ATE203747T1 (de) 5-azabicyclo(3.1.0.)hexylalkyl-2-piperidone und - glutarimide als neurokinin receptor antagonisten.
CO5261565A1 (es) Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina
CO5150219A1 (es) Inhibidores de metaloproteasa que contiene alquenilo y alque nilo que son efectivos en el tratamiento de condiciones ca- racterizadas por actividad excesiva de estas enzimas
RU94034117A (ru) Производные азола, способы их получения и антигрибковое средство
NO20003773L (no) Syklobutenderivater, deres fremstilling og deres terapeutiske anvendelser
CO5261594A1 (es) Inhibidores de myt1 cinasa
CO5251439A1 (es) Compuestos calciliticos
DK0875506T3 (da) Quinolin- og quinazolin-forbindelser, som er anvendelige til behandling